Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Simon Bryson"'
Publikováno v:
Pharmaceutics, Vol 15, Iss 2, p 556 (2023)
The rapid onset of action of nifedipine causes a precipitous reduction in blood pressure leading to adverse effects associated with reflex sympathetic nervous system (SNS) activation, including tachycardia and worsening myocardial and cerebrovascular
Externí odkaz:
https://doaj.org/article/06ba2c144adc41f5bf7703dd1497da8a
Publikováno v:
Pharmaceutics, Vol 13, Iss 6, p 831 (2021)
Owing to considerable differences observed in anatomy and physiology between paediatric subsets, it has been well established that children respond to drugs differently compared to adults. Furthermore, from a formulation perspective, there is a disti
Externí odkaz:
https://doaj.org/article/65a8261922b142e3af4b3c156079b935
Publikováno v:
International journal of pharmaceutics. 616
The total number of paediatric formulations available only account for a small proportion of the full therapeutic plethora required to effectively treat paediatrics and, therefore, the availability of high quality medicines designed specifically for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ad765a65b839ac0d7fc84846227cece
https://pubmed.ncbi.nlm.nih.gov/35092832
https://pubmed.ncbi.nlm.nih.gov/35092832
Publikováno v:
Pharmaceutics
Volume 13
Issue 6
Pharmaceutics, Vol 13, Iss 831, p 831 (2021)
Volume 13
Issue 6
Pharmaceutics, Vol 13, Iss 831, p 831 (2021)
Owing to considerable differences observed in anatomy and physiology between paediatric subsets, it has been well established that children respond to drugs differently compared to adults. Furthermore, from a formulation perspective, there is a disti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9c7942d6e9cb3f6244763ff246c407b
Publikováno v:
Archives of Disease in Childhood. 105:e18.1-e18
Background & AimAs part of the EU paediatric regulation, the paediatric use marketing authorisation (PUMA) was introduced, with an aim to stimulate research in existing compounds that are off-patent and/or to help transform known off-label use into a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6dcd65c03418773a9681a5d115205541
https://doi.org/10.1136/archdischild-2020-nppg.32
https://doi.org/10.1136/archdischild-2020-nppg.32
Autor:
Simon Bryson
Publikováno v:
Journal of Commercial Biotechnology. 8
1st May, 2001, saw the final publication of the long-anticipated European Union Directive relating to Good clinical practice in the conduct of clinical trials on medicinal products for human use (2001/20/EC). The Directive consolidates, for the first
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7bacfd3cee5b3d3b368e17788875478
https://doi.org/10.5912/jcb410
https://doi.org/10.5912/jcb410